Parsortix is a simple blood test that detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer.
Researchers at the Medical University of Vienna looked for neuroendocrine markers on these CTCs, which were found to correlate with patients’ overall survival: the more markers, the more aggressive the cancer.
Not only could this speed up a patient’s initial diagnosis, but further liquid biopsies could also help to guide treatment plans as the cancer evolves.
RNA analysis of the CTCs could also help determine which drugs are likely to be most effective for a particular patient.
Professor Robert Zeillinger, head of the Molecular Oncology Group at the university, said this new approach has “the potential to significantly improve the way that lung cancer is diagnosed and treated”.
ANGLE founder and chief executive Andrew Newland added: “Lung cancer is a major opportunity for ANGLE to pursue once we have concluded our current FDA and verification studies in breast cancer and ovarian cancer.
“We are encouraged by the work of Vienna, and others, in this area. There is a clear benefit to lung cancer patients in faster diagnosis, longitudinal monitoring and reducing invasive procedures as well as a strong health economic argument to reduce healthcare costs.”